Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study
Open Access
- 13 January 2025
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf016
Abstract
Background: HIV viremia has been considered a cardiovascular disease (CVD) risk factor, but many studies have had insufficient data on potential confounders. We explored the association between viremia and CVD after adjusting for established risk factors and analyzed whether consideration of viremia would improve CVD prediction. Methods: Adults from RESPOND were followed from the first date with available data until the first of rigorously defined CVD, loss to follow-up, death, or administrative censoring. We first analyzed the associations between 6 measures of viremia (time-updated, before antiretroviral therapy [ART], viremia category, and measures of cumulative viremia) and CVD after adjusting for the variables in the D:A:D CVD score (age, sex/gender, smoking, family history, diabetes, recent abacavir, CD4 count, blood pressure, cholesterol, high-density lipoprotein, cumulative use of stavudine, didanosine, indinavir, lopinavir, and darunavir). We subsequently compared predictive performance with and without viremia in 5-fold internal cross-validation. Results: A total of 547 events were observed in 17 497 persons (median follow-up, 6.8 years). Although some viremia variables were associated with CVD in univariable analyses, there were no statistically significant associations after adjusting for potential confounders, neither for measures of current viral load, pre-ART viral load, highest viremia category during ART, nor cumulative viremia (modeled both as total cumulative viremia, cumulative viremia during ART, and recent cumulative viremia). Consistently, none of the viremia variables improved prediction capacity. Conclusions: In this large international cohort, HIV viremia was not associated with CVD when adjusting for established risk factors. Our results did not show viremia to be predictive of CVD among people with HIV.Keywords
Funding Information
- International Cohort Consortium of Infectious Disease
- RESPOND
- CHU St Pierre Brussels HIV Cohort
- Austrian HIV Cohort Study
- Australian HIV Observational Database
- AIDS Therapy Evaluation
- Netherlands National Observational HIV cohort
- EuroSIDA cohort
- Frankfurt HIV Cohort Study
- Georgian National AIDS Health Information System
- Nice HIV Cohort
- ICONA Foundation
- Modena HIV Cohort
- PISCIS Cohort Study
- Swiss HIV Cohort Research Foundation
- San Raffaele Scientific Institute
- University Hospital Bonn HIV Cohort
- University of Cologne HIV Cohort
- ViiV Healthcare
- Merck Life Sciences
- Gilead Sciences
- EuroSIDA cohort
- AHOD cohort (GNT2023845)
- National Health and Medical Research Council
- Swedish Heart-Lung Foundation (20230335)
- Swedish Physicians Against AIDS Research Foundation (FOb2003-0007)
- Department of Research and Development (0825-011 8298)
This publication has 41 references indexed in Scilit:
- Episodes of HIV Viremia and the Risk of Non-AIDS Diseases in Patients on Suppressive Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare SystemJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs StudyEuropean Journal of Preventive Cardiology, 2010
- Low CD4+T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient StudyClinical Infectious Diseases, 2010
- Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort StudiesClinical Infectious Diseases, 2010
- Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral BurdenAmerican Journal of Epidemiology, 2009
- Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapyAIDS, 2009
- Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART TrialAntiviral Therapy, 2008
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentNew England Journal of Medicine, 2006
- Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancerStatistics in Medicine, 2004